Tag: strategy

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

Partnership with leading robotic lawn mower developer marks strategic diversification beyond automotive intelligence sector

DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- CoinBom has officially launched its new AI-Powered Copy Trading System, marking a significant milestone in the platform’s continued commitment to intelligent wealth management and quantitative investment. This system integrates advanced AI algorithms with cyclical trading strategies, offering users a more stable and efficient way to grow their digital asset portfolios.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SkyCrest Capital, a global fintech innovator, today announced the launch of its transformative Pension Plan, a structured asset growth initiative set to begin on Monday, June 23, 2025. Powered by the proprietary SAX-iCore AI Structural Recognition System and executed via the LEXO decentralized trading platform, the plan targets a 150% net return in its first week, offering individual traders and investors a disciplined, AI-driven path to wealth accumulation.

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.